Clinical trials
Colorectal Cancer (Locally Advanced or Metastatic) clinical trials
Below are recruiting colorectal cancer (locally advanced or metastatic) clinical trials, each written for real people, not researchers. We’re tracking 5,580 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT05790850Recruiting
Mindfulness and exercise plan before bladder surgery
This study tests whether a structured mindfulness and high-intensity exercise program before radical bladder surgery can help patients improve health and recovery. You may be asked to use monitoring devices and complete questionnaires during the study.
Charlottesville, VirginiaAges 18–90 - NCT05798338Recruiting
Study blood samples and tiny cell particles in breast cancer
This study looks at tiny particles released by cells (called extracellular vesicles) in people with breast cancer. It may help researchers better understand breast cancer and how it behaves, which could improve future testing or treatments.
Pavia, LombardyAges 18–90 - NCT05808634RecruitingPhase 1
Testing an investigational drug for advanced lung or gut cancer
This Phase 1 trial tests BA3182, an investigational medicine, in people with advanced adenocarcinoma that cannot be removed by surgery. The goal is to see how the treatment works and whether it’s tolerated, and it may offer an option when standard options have been limited.
Irvine, CaliforniaAges 18 years+ - NCT05811936Recruiting
SNAP support tool for head and neck cancer survivors and caregivers
This trial tests a “SNAP” support tool designed for people who have head and neck cancer and the caregiver who helps them. It aims to improve support and coping during and after cancer treatment by involving both the survivor and their main support person.
Charleston, South CarolinaAges 18 years+ - NCT05817617Recruiting
Vitamin D use in head and neck cancer
This study looks at how taking vitamin D may affect side effects (toxicity) and outcomes in people with locally advanced head and neck squamous cell cancer. It may help improve comfort during treatment and track whether vitamin D changes prognosis.
Barletta, BATAges 18 years+ - NCT05832736Recruiting
Robot surgery for one-sided prostate cancer with urethra preserved
This study looks at a robotic prostate operation that aims to remove only the affected side while keeping the urethra (the tube for urination) to help preserve urinary function. It’s for people with low- to intermediate-risk, one-sided prostate cancer and no spread to lymph nodes, bones, or other organs.
Candiolo, TOAges 40 years+ - NCT05834413Recruiting
Herbs plus chemo and immunotherapy to prevent lung cancer spread
This study looks at whether staged Chinese herbal medicine added to standard treatment can lower the risk of lung cancer coming back or spreading after surgery. It is for people with stage Ib to IIIb non-small cell lung cancer whose tests show no “driver gene” targets.
Shanghai, Shanghai MunicipalityAges 18–74 - NCT05838729RecruitingPhase 1/Phase 2
RiMO-301 plus radiation with PD-1 therapy for head-neck cancer
This trial studies RiMO-301 injection combined with palliative radiation and a PD-1 immune therapy (pembrolizumab or nivolumab) for head and neck cancer that cannot be fully removed. It aims to see whether this approach can shrink tumors and improve outcomes safely.
Chicago, IllinoisAges 18 years+ - NCT05841420RecruitingPhase 2
Lower-intensity chemo for fragile pancreatic cancer patients
This Phase 2 trial compares a standard gemcitabine approach versus a reduced-dose combination chemotherapy for people with pancreatic cancer that can’t be removed by surgery. It aims to find a treatment that works while being safer for “fragile” patients who can’t tolerate full-dose chemotherapy.
AalborgAges 18 years+ - NCT05847166Recruiting
Testing a PSMA-targeted treatment for prostate cancer
This trial studies a treatment that targets a protein called PSMA in people with prostate cancer. It may help shrink or control the cancer and is being tested in different risk groups and stages of disease.
Bydgoszcz, PolandAges 18 years+ - NCT05862064RecruitingPhase 3
Adding an immune drug and anti-blood-vessel treatment to chemo
This study tests whether adding an immune therapy (a PD-1 antibody) plus a blood-vessel–blocking treatment to standard chemo improves outcomes for people with surgically treated triple-negative breast cancer. Everyone gets chemotherapy, but some will also get the added drugs to try to reduce cancer coming back.
Shanghai, Shanghai MunicipalityAges 18–70 - NCT05868629Recruiting
Test of two targeted drugs for tumors with BRAF V600E
This trial tests dabrafenib plus trametinib in people whose solid tumors have a BRAF V600E mutation that cannot be fully removed by surgery or has spread. It looks at whether these targeted medicines can shrink tumors and control the disease.
Torrance, CaliforniaAges 1–100 - NCT05882253Recruiting
Test MRI-guided biopsy for early prostate cancer detection
This study uses a special MRI-guided (MRI-fusion) needle biopsy to look for early prostate cancer. It may help find concerning areas more accurately before cancer spreads.
La Jolla, CaliforniaAges Any age - NCT05887102Recruiting
Program to help women take hormone pills after breast cancer
This study tests a pharmacy-based program (called PACHA) designed to help women remember and stick with hormone (endocrine) treatment after breast cancer. It may help by improving support and follow-through during the first months after starting the pills.
Québec, QuebecAges 18 years+ - NCT05891093RecruitingPhase 3
Fluzoparib plus hormone therapy after surgery for breast cancer
This Phase 3 trial tests whether fluzoparib added to standard hormone (endocrine) therapy after early breast cancer surgery can improve outcomes and safety. It may help patients whose tumors are ER-positive, HER2-negative, and a specific SNF3 subtype.
Beijing, Beijing MunicipalityAges 18–70 - NCT05891561RecruitingPhase 2
Short antibody treatment after surgery for early HER2+ breast cancer
This Phase 2 study tests a shorter schedule of trastuzumab and pertuzumab combined with chemotherapy (taxanes) to reduce breast cancer coming back after surgery. It mainly helps people with early-stage, HER2-positive breast cancer that has not spread, by testing whether a shorter plan still works well and is tolerable.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT05893381RecruitingPhase 2
Targeted PSMA scan plus focused radiation vs radiation alone
This trial tests whether adding a PSMA-targeted radioactive medicine (Lu-PSMA) to focused stereotactic radiation to a few prostate cancer spots works better than radiation alone. It may help people with limited, asymptomatic spread of prostate cancer by improving cancer control while carefully monitoring side effects.
Cesena, FCAges 18 years+ - NCT05894824RecruitingPhase 1/Phase 2
T-DXd with ramucirumab for HER2-low stomach and GEJ cancer
This trial studies T-DXd given with ramucirumab to treat stomach (gastric) or stomach–esophagus junction (GEJ) cancer that has spread or is locally advanced and is “HER2-low.” It’s mainly to test safety and early effectiveness in people whose cancer continued after first-line treatment.
Seoul, SeoulAges 19 years+ - NCT05909332RecruitingPhase 3
Tested antivascular drug plus chemo versus chemo alone for TNBC
This Phase 3 trial compares an “anti-blood-vessel” drug added to chemotherapy versus chemotherapy alone for people with stage II–IIIC triple-negative breast cancer that has been completely removed with surgery. The goal is to see if adding the study drug improves outcomes after surgery (adjuvant treatment).
Beijing, Beijing MunicipalityAges 18–70 - NCT05909111Recruiting
Testing a radiation plan for cervical cancer using MRI guidance
This feasibility study tests whether an MRI-guided radiation approach can be used safely and practically for people with certain stages of cervical cancer. It’s meant to help doctors plan radiation more accurately, while checking whether the treatment process works well.
AvignonAges 18 years+ - NCT05911217RecruitingPhase 1
CT041 treatment after chemotherapy for resected pancreatic cancer
This Phase 1 study tests whether CT041 is safe and may help prevent pancreatic cancer from coming back after it’s been removed and you’ve completed standard chemotherapy. You may be eligible if your tumor is positive for CLDN18.2 and your recovery and blood tests meet key requirements.
Beijing, Beijing MunicipalityAges 18–79 - NCT05913388RecruitingPhase 2
Testing a new drug plus pembrolizumab versus pembrolizumab alone
This Phase 2 trial studies whether adding GB1211 to pembrolizumab works better than pembrolizumab with a placebo in people with metastatic melanoma or metastatic head and neck squamous cell cancer. It may help shrink tumors and improve outcomes, but it also carries risks from immune-based treatment.
Portland, OregonAges 18 years+ - NCT05916040Recruiting
MRI-guided treatment for locally advanced rectal cancer
This trial studies a total “before-surgery” treatment plan for locally advanced rectal cancer, using MRI (a detailed scan) to help guide radiation. It may help patients by aiming to shrink the tumor and improve the chance of successful surgery.
Jette, Brussels CapitalAges 18 years+ - NCT05916755Recruiting
Testing tumor clues that predict response to immunotherapy
This study looks for “biomarkers,” or tumor clues, that may help predict who benefits from checkpoint inhibitor immunotherapy in triple-negative breast cancer. It may help doctors choose the right treatment approach in the future, especially when chemotherapy is planned.
BarcelonaAges 18 years+
Hear when a new Colorectal Cancer (Locally Advanced or Metastatic) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for colorectal cancer (locally advanced or metastatic)?
- Yes. Clin2 currently lists 5,580 recruiting colorectal cancer (locally advanced or metastatic) studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a colorectal cancer (locally advanced or metastatic) trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a colorectal cancer (locally advanced or metastatic) trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- Locally Advanced or Metastatic Breast Cancer
- Locally Advanced or Metastatic Non-small Cell Lung Cancer
- Locally Advanced Colorectal Cancer
- Lung Cancer (Locally Advanced or Metastatic)
- Liver Cancer (Locally Advanced or Metastatic)
- Metastatic Colorectal Cancer
- Locally Advanced Rectal Cancer
- Metastatic Colorectal Cancer (CRC)
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.